Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey

Figures & data

Figure 1. Characteristics of surveyed participants. VVA, vulvovaginal atrophy.

Table 1. Baseline characteristics of surveyed population of women reporting symptoms of vulvovaginal atrophy (VVA) (n = 3768). Data are given as n (%).

Age (years)
45–50	363 (9.6%)
51–55	1163 (30.9%)
56–60	1091 (29.0%)
61–65	715 (19.0%)
66–70	329 (8.7%)
71–75	107 (2.8%)
Marital status
Married	2364 (62.7%)
Divorced	516 (12.9%)
Domestic partnership	349 (8.7%)
Single	283 (7.1%)
Widowed	209 (5.2%)
Separated	128 (3.2%)
Education/employment
Employed	1317 (35.0%)
University education or higher^a	1380 (36.6%)
Number of children
None	758 (20.1%)
One	910 (24.2%)
Two	1441 (38.2%)
Three	475 (12.6%)
Four or more	184 (4.9%)
Children living at home	1421 (47.2%)
Prior treatment for VVA symptoms	2554 (67.8%)
OTC product	1545 (41.0%)
Prescription medication	382 (10.1%)
Prescription and OTC in combination	450 (11.9%)
Current treatment for VVA symptoms	1703 (45.2%)
OTC product	1138 (30.2%)
Prescription medication	341 (9.0%)
Prescription and OTC in combination	72 (1.9%)

^aIncludes trade training, degrees and master’s degrees.

OTC, over the counter.

Figure 2. Onset of vulvovaginal atrophy (VVA) symptoms in participants currently suffering from VVA.

Figure 3. Interference of symptoms of vulvovaginal atrophy with sexual life and other activities.

Figure 4. Current use of treatment by participants.

Figure 5. Proportion of participants concerned with long-term use of their current vulvovaginal atrophy medication. OTC, over the counter.

Table 2. Views of therapies for vulvovaginal atrophy (VVA) in participants currently using treatment. Data are given as n (%).

	OTC personal vaginal moisturizer (n = 809)	OTC vaginal lubricant (n =308)	Prescription vaginal (n =381)
Issues related to route of administration
Messy	76 (9.4%)	57 (18.5%)	51 (13.3%)
Not discrete	28 (3.5%)	8 (2.6%)	12 (3.1%)
Not an oral pill	68 (8.4%)	14 (4.5%)	28 (7.3%)
Do not like touching body	17 (2.1%)	7 (2.3%)	8 (2.1%)
Issues related to convenience
Interrupts my daily activities/life	12 (1.5%)	4 (1.3%)	6 (1.6%)
Inconvenient to administer	64 (7.9%)	22 (7.1%)	58 (15.2%)
Cannot be sexually spontaneous	121 (15.0%)	39 (12.7%)	31 (8.1%)
Difficult dosing schedule	28 (3.5%)	4 (1.3%)	17 (4.5%)
Procedure of administering treatment	52 (6.4%)	13 (4.2%)	44 (11.5%)
Issues related to side-effects/safety
Concern about breast cancer	31 (3.8%)	4 (1.3%)	43 (11.3%)
Concern about hormone exposure	41 (5.1%)	5 (1.6%)	63 (16.5%)
Concern about safety in long-term use	88 (10.9%)	36 (11.7%)	81 (21.3%)
Vaginal discharge	51 (6.3%)	16 (5.2%)	57 (15.0%)
Concern about other side-effects	70 (8.7%)	16 (5.2%)	62 (16.3%)
Experienced side-effects	14 (1.7%)	4 (1.3%)	6 (1.6%)
Partner absorbing estrogen	14 (1.7%)	2 (0.6%)	15 (3.9%)
Issues related to efficacy
Vagina not restored to natural state	225 (27.8%)	87 (28.2%)	98 (25.7%)
Not enough relief of symptoms	106 (13.1%)	37 (12.0%)	49 (12.9%)
Takes a long time to start working	61 (7.5%)	18 (5.8%)	46 (12.1%)
Other
Expensive	115 (14.2%)	30 (9.7%)	26 (6.8%)
Negative impact on intimacy	23 (2.8%)	7 (2.3%)	3 (0.8%)

OTC, over the counter.